China’s State FDA Halts Use of Lethal Tangzhining Capsules
This article was originally published in PharmAsia News
Executive Summary
On receiving China's State FDA report that Tangzhining Capsule manufactured by Guangxi Pingnan Pharmaceutical has caused two deaths, China's Ministry of Health issued an emergency notice on Jan. 30 asking medical institutions to immediately halt its use. MOH wants drugs with the label to be registered and sent for testing. According to reports, two diabetics in Kashi precinct, Xinjiang Uygur Autonomous Region died after taking capsules from the batch. Guangxi FDA's investigations found that Guangxi Pingnan never produced the implicated drugs. After examination, the Institute for Drug Control of Xinjiang Uygur Autonomous Region confirmed that the fake drugs had illicit chemical substance glibenclamide added. (Click here for more - Chinese Language)